PPAR Regulation of Inflammatory Signaling in CNS Diseases
Author Information
Author(s): John J. Bright, Kanakasabai Saravanan, Chearwae Wanida, Chakraborty Sharmistha
Primary Institution: Neuroscience Research Laboratory, Methodist Research Institute, Clarian Health, Indianapolis, IN, USA
Hypothesis
The activation of PPARs can mitigate neuroinflammatory diseases by modulating inflammatory signaling networks.
Conclusion
PPAR agonists show potential in treating various neuroinflammatory diseases by regulating immune responses and inflammatory signaling.
Supporting Evidence
- PPAR agonists have been shown to reduce inflammation in models of multiple sclerosis.
- Treatment with pioglitazone improved cognitive function in Alzheimer's patients.
- PPARĪ³ agonists can inhibit the activation of microglia and astrocytes, which are involved in neuroinflammation.
- PPARĪ± agonists have protective effects in models of stroke and traumatic brain injury.
- Clinical trials suggest that PPAR agonists may reduce the risk of developing neurodegenerative diseases.
Takeaway
This study looks at how certain drugs can help reduce inflammation in the brain, which is important for diseases like multiple sclerosis and Alzheimer's.
Methodology
The study reviews existing literature on the effects of PPAR agonists in various neuroinflammatory disease models.
Limitations
The exact mechanisms of how PPAR agonists work are not fully understood.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website